Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

23 Mar 20265 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Chronic Obstructive Pulmonary Disease · Phase 3 · Enrollment 942 · Sponsor: Sanofi

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Critical Care on 23 Mar 2026. The item focuses on Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype. Open the detail page to review the full original feed content.